The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Open accessAbstract
BACKGROUND: Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS: In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10(6), 1×10(6), or 3×10(6) IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×10(6) IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P<0.001), without affecting CD4+ conventional T (Tcon) cells. The Treg:Tcon ratio increased to a median of more than five times the baseline value (P<0.001). The Treg cell count and Treg:Tcon ratio remained elevated at 8 weeks (P<0.001 for both comparisons with baseline values), then declined when the patients were not receiving interleukin-2. The increased numbers of Treg cells expressed the transcription factor forkhead box P3 (FOXP3) and could inhibit autologous Tcon cells. Immunologic and clinical responses were sustained in patients who received interleukin-2 for an extended period, permitting the glucocorticoid dose to be tapered by a mean of 60% (range, 25 to 100). CONCLUSIONS: Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy. Administration was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GVHD in a substantial proportion of patients. (Funded by a Dana-Farber Dunkin' Donuts Rising Star award and others; ClinicalTrials.gov number, NCT00529035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
Self-citationFilipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.004 · Cited by 3,556
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512
Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C. G., Strober, S., & Negrin, R. S. (2003) · Nature Medicine · doi:10.1038/nm915 · Cited by 1,288
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., McDevitt, H., Bonyhadi, M., & Bluestone, J. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040139 · Cited by 1,221
Hoffmann, P., Ermann, J., Edinger, M., Fathman, C. G., & Strober, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020399 · Cited by 1,098
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., Del Papa, B., Zei, T., Ostini, R. I., Cecchini, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311894 · Cited by 1,064
Brunstein, C. G., Miller, J. S., Cao, Q., McKenna, D. H., Hippen, K. L., Curtsinger, J., DeFor, T., Levine, B. L., June, C. H., Rubinstein, P., et al. (2011) · Blood · doi:10.1182/blood-2010-07-293795 · Cited by 1,045
Cited by
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Liao, W., Lin, J.-X., & Leonard, W. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.004 · Cited by 1,075
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., & Klatzmann, D. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105143 · Cited by 762
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Weirather, J., Hofmann, U. D. W., Beyersdorf, N., Ramos, G. C., Vogel, B., Frey, A., Ertl, G., Kerkau, T., & Frantz, S. (2014) · Circulation Research · doi:10.1161/circresaha.115.303895 · Cited by 699
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, D., & Abbas, A. K. (2015) · Nature Reviews Immunology · doi:10.1038/nri3823 · Cited by 636
Revisiting IL-2: Biology and therapeutic prospects
Abbas, A. K., Trotta, E., R. Simeonov, D., Marson, A., & Bluestone, J. A. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat1482 · Cited by 636
He, J., Zhang, X., Wei, Y., Sun, X., Chen, Y., Deng, J., Jin, Y., Gan, Y., Hu, X., Jia, R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4148 · Cited by 572
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539
Mechanisms of human autoimmunity
Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78088 · Cited by 515
Next-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
Cooke, K. R., Luznik, L., Sarantopoulos, S., Hakim, F. T., Jagasia, M., Fowler, D. H., van den Brink, M. R. M., Hansen, J. A., Parkman, R., Miklos, D. B., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2016.09.023 · Cited by 472
Self-citationMatsuoka, K.-I., Koreth, J., Kim, H. T., Bascug, G., McDonough, S., Kawano, Y., Murase, K., Cutler, C., Ho, V. T., Alyea, E. P., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005265 · Cited by 468
Self-citationImmune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
Ogonek, J., Kralj Juric, M., Ghimire, S., Varanasi, P. R., Holler, E., Greinix, H., & Weissinger, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00507 · Cited by 458
Regulatory immune cells in transplantation
Wood, K. J., Bushell, A., & Hester, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3227 · Cited by 431
Hartemann, A., Bensimon, G., Payan, C. A., Jacqueminet, S., Bourron, O., Nicolas, N., Fonfrede, M., Rosenzwajg, M., Bernard, C., & Klatzmann, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70113-x · Cited by 428
Homeostatic control of regulatory T cell diversity
Liston, A., & Gray, D. H. D. (2014) · Nature Reviews Immunology · doi:10.1038/nri3605 · Cited by 427
Romee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Rosenzwajg, M., Lorenzon, R., Cacoub, P., Pham, H. P., Pitoiset, F., El Soufi, K., RIbet, C., Bernard, C., Aractingi, S., Banneville, B., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214229 · Cited by 405
From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines
Banchereau, J., Pascual, V., & O'Garra, A. (2012) · Nature Immunology · doi:10.1038/ni.2406 · Cited by 401
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Spoerl, S., Mathew, N. R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-543736 · Cited by 401
Bailey-Bucktrout, S. L., Martinez-Llordella, M., Zhou, X., Anthony, B., Rosenthal, W., Luche, H., Fehling, H. J., & Bluestone, J. A. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.016 · Cited by 396
The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Leonard, W. J., Lin, J.-X., & O'Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 383
How we treat chronic graft-versus-host disease
Flowers, M. E. D., & Martin, P. J. (2015) · Blood · doi:10.1182/blood-2014-08-551994 · Cited by 371
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Regulatory T cells delay disease progression in Alzheimer-like pathology
Dansokho, C., Ait Ahmed, D., Aid, S., Toly-Ndour, C., Chaigneau, T., Calle, V., Cagnard, N., Holzenberger, M., Piaggio, E., Aucouturier, P., et al. (2016) · Brain · doi:10.1093/brain/awv408 · Cited by 359
Interleukin-2: Biology, Design and Application
Arenas-Ramirez, N., Woytschak, J., & Boyman, O. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.10.003 · Cited by 359
Engineering IL-2 for immunotherapy of autoimmunity and cancer
Hernandez, R., Põder, J., LaPorte, K. M., & Malek, T. R. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00680-w · Cited by 355
von Spee-Mayer, C., Siegert, E., Abdirama, D., Rose, A., Klaus, A., Alexander, T., Enghard, P., Sawitzki, B., Hiepe, F., Radbruch, A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207776 · Cited by 349
He, J., Zhang, R., Shao, M., Zhao, X., Miao, M., Chen, J., Liu, J., Zhang, X., Zhang, X., Jin, Y., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215396 · Cited by 345
Regulatory T-Cells: Potential Regulator of Tissue Repair and Regeneration
Li, J., Tan, J., Martino, M. M., & Lui, K. O. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00585 · Cited by 344
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Emerging cell and cytokine targets in rheumatoid arthritis
Burmester, G. R., Feist, E., & Dörner, T. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.168 · Cited by 307
Immune-mediated pathology in Duchenne muscular dystrophy
Rosenberg, A. S., Puig, M., Nagaraju, K., Hoffman, E. P., Villalta, S. A., Rao, V. A., Wakefield, L. M., & Woodcock, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7322 · Cited by 304
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
MacDonald, K. P. A., Hill, G. R., & Blazar, B. R. (2017) · Blood · doi:10.1182/blood-2016-06-686618 · Cited by 300
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
West, E. E., Jin, H.-T., Rasheed, A.-U., Penaloza-MacMaster, P., Ha, S.-J., Tan, W. G., Youngblood, B., Freeman, G. J., Smith, K. A., & Ahmed, R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67008 · Cited by 298
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Wagner, J. A., Rosario, M., Romee, R., Berrien-Elliott, M. M., Schneider, S. E., Leong, J. W., Sullivan, R. P., Jewell, B. A., Becker-Hapak, M., Schappe, T., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90387 · Cited by 297
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Wachsmuth, L. P., Patterson, M. T., Eckhaus, M. A., Venzon, D. J., Gress, R. E., & Kanakry, C. G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124218 · Cited by 292
Treatment strategies for autoimmune encephalitis
Shin, Y.-W., Lee, S.-T., Park, K.-I., Jung, K.-H., Jung, K.-Y., Lee, S. K., & Chu, K. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 266
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy
Bhattacharya, P., Budnick, I., Singh, M., Thiruppathi, M., Alharshawi, K., Elshabrawy, H., Holterman, M. J., & Prabhakar, B. S. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0149 · Cited by 264
Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression
Sharma, M., Schlegel, M. P., Afonso, M. S., Brown, E. J., Rahman, K., Weinstock, A., Sansbury, B. E., Corr, E. M., van Solingen, C., Koelwyn, G. J., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316461 · Cited by 259
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
Rosenzwajg, M., Churlaud, G., Mallone, R., Six, A., Dérian, N., Chaara, W., Lorenzon, R., Long, S. A., Buckner, J. H., Afonso, G., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.01.001 · Cited by 257
Pathophysiology of GvHD and Other HSCT-Related Major Complications
Ghimire, S., Weber, D., Mavin, E., Wang, X. N., Dickinson, A. M., & Holler, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00079 · Cited by 256
Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?
Hull, C. M., Peakman, M., & Tree, T. I. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4377-1 · Cited by 194
Approaches and advances in the genetic causes of autoimmune disease and their implications
Inshaw, J. R. J., Cutler, A. J., Burren, O. S., Stefana, M. I., & Todd, J. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0129-8 · Cited by 70
Fibrosing connective tissue disorders of the skin: Molecular similarities and distinctions
Canady, J., Karrer, S., Fleck, M., & Bosserhoff, A. K. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.03.005 · Cited by 66
Caramalho, I., Nunes-Silva, V., Pires, A. R., Mota, C., Pinto, A. I., Nunes-Cabaço, H., Foxall, R. B., & Sousa, A. E. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.11.002 · Cited by 42
Ferreira, R. C., Rainbow, D. B., Rubio García, A., Pekalski, M. L., Porter, L., Oliveira, J. J., Waldron-Lynch, F., Wicker, L. S., & Todd, J. A. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.03.002 · Cited by 19
Sekiya, T., Kasahara, H., Takemura, R., Fujita, S., Kato, J., Doki, N., Katayama, Y., Ozawa, Y., Takada, S., Eto, T., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100808 · Cited by 16
Regulatory T Cells: Central Concepts from Ontogeny to Therapy
Khor, B. (2017) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2016.07.003 · Cited by 15
“8 × 10 IU/kg daily in cancer) to attenuate the inflammation in GVHD and HCV vasculitis [81-83].”
Background
Metadata
- Authors
- Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., Bienfang, D. C., Prasad, S., Tzachanis, D., Joyce, R. M., Avigan, D. E., Antin, J. H., Ritz, J., & Soiffer, R. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12
- Volume
- 365
- Issue
- 22
- Pages
- 2055-2066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2086030126
- Cited by
- 1,119
- References
- 39
- FWCI
- 46.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.